Tyra Biosciences, Inc. filed an 8-K on September 9, 2026, disclosing initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, along with updates from two additional studies.
Key Highlights
- Efficacy at 60 mg QD: The overall response rate in the combined single and multiple marker lesion population was 79% (11/14) at the 3-month assessment and best overall response (BOR), with a complete response rate of 64% (9/14) at BOR.
- Single marker lesion response: Among 60 mg QD participants with a single marker lesion (n=8), ORR reached 100% (8/8) at both the 3-month assessment and BOR.
- Safety profile at 60 mg QD: No Grade 4 or 5 TEAEs were reported; Grade 3 TEAEs occurred in 3 participants (14%) at 60 mg QD, and there were no dose reductions or treatment-related discontinuations at that dose level.
- Dose selection: The company identified 60 mg once-daily as the potential dose supporting its planned registrational adjuvant development strategy, with plans to initiate a 70 mg QD cohort for the ablative setting.
- Durability signal: All 3-month complete responders who reached the 6-month assessment remained in response (n=5), and the first study participant remained in CR at 12 months and continued on study drug at 14 months.
- SURF303 observation: The first patient treated in the SURF303 study achieved a complete response at the 3-month assessment at 60 mg QD, with no observed TEAEs, as of the August 31, 2026 data cutoff.
- BEACH301 update: The company reported clearance of the fifth dose level with no safety signals in the safety sentinel cohort (ages 5 to 10) of its pediatric achondroplasia study.
SURF302 Initial Results: Safety, Efficacy, and Dose Strategy for Dabogratinib in Bladder Cancer
According to the filing, as of the August 31, 2026 data cutoff, Tyra Biosciences reported initial safety and tolerability results for oral dabogratinib across the 60 mg QD (n=22) and 50 mg QD (n=22) dose cohorts in SURF302. The company disclosed that most treatment-emergent adverse events were Grade 1 or 2. Grade 3 treatment-related adverse events occurred in 2 of 44 participants (4.5%) across both cohorts, both at the 50 mg QD dose, with none at 60 mg QD. No clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity was observed, and transaminase TEAEs were reported at a frequency of less than 10%.
For efficacy, 26 participants were evaluable across both cohorts as of the data cutoff. In the combined single and multiple marker lesion population at 60 mg QD (n=14), the filing reported an ORR of 79% (11/14) and a BOR complete response rate of 64% (9/14). Preliminary exposure-response analyses showed an ORR of 86% (12/14) among participants with steady-state exposure above an AUC threshold of 2500 ng.hr/mL, compared with 58% (7/12) among those below the threshold, according to the filing. The company disclosed that approximately 61% of enrolled patients had no prior lines of intravesical treatment, characterizing the population as "highly recurrent, undertreated."
The filing also disclosed that TYRA plans to complete enrollment in the 60 mg QD cohort, initiate a 70 mg QD cohort, and engage health authorities on Phase 3 study design, with a planned registrational adjuvant study expected to be initiated in 2027. The company estimated a potential total market opportunity for IR NMIBC of greater than $5 billion, based on third-party market research and assuming full penetration of branded agents across the FGFR3-altered patient population. The filing notes that forward-looking statements are the company's own and are subject to risks and uncertainties described in the report. Tyra Biosciences, Inc. is listed on the Nasdaq Global Select Market under the ticker NASDAQ:TYRA.
What Was Disclosed
Tyra Biosciences filed an 8-K on September 9, 2026, disclosing initial Phase 2 data for oral dabogratinib in bladder cancer, a first patient observation in LG UTUC, and a pediatric achondroplasia study dose-level clearance, all as of an August 31, 2026 data cutoff.




Please wait processing your request...